IPCH treatment combines many advantages, including (1) 43°C kills and apoptoses tumor cells, leaving normal tissues unaffected (2) thermochemotherapy increases the sensitivity of tumor cells to chemotherapeutic agents (3) higher concentrations of local dosing and less systemic response (4) mechanical washout and filtration of free cancer cells. For IPCH, it is best to perform it intraoperatively and early postoperatively.
The advantages of performing IPCH at this time are:
(1) when IPCH is performed intraoperatively, the patient is under anesthetic supervision, well tolerated and safe (2) the resected site and the surgically damaged peritoneal surface are most prone to cancer cell implantation and recurrence in the postoperative period, so IPCH should be supplemented with timely treatment (3) when the adhesions are thoroughly separated intraoperatively and IPCH is performed before the formation of abdominal adhesions, all peritoneal surfaces can be in full contact with the chemotherapeutic solution (4) at this time, the tumor load in the patient’s body is minimal and the tumor cells are dividing. tumor load is minimal, and tumor cells divide and proliferate faster and are sensitive to anticancer drugs(5)
After 3-5 days postoperatively, the formation of abdominal adhesions can lead to line incompetence, and patients are prone to abdominal pain and bloating during treatment and refuse or cannot receive treatment. The introduction of IPHC machine will not only help our patients with peritoneal implantation tumors, but will also change our treatment philosophy for some patients with progressive gastric cancer. Hopefully, it will significantly prolong the survival of this patient today, and hopefully more patients will benefit from our treatment.